

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-92) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT:

(Use several sheets if necessary)

ATTY. DOCKET NO.: 017620/9324

SERIAL NO.: 09/891,814

APPLICANT: Bishop et al

FILING DATE: June 26, 2001

GROUP: 1614



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A	4,554,106	Nov 19, 1985	DeLuca et al			
	B	4,670,190	Jun 2, 1987	Hesse et al			
	C	5,486,636	Jan 23, 1996	DeLuca et al			
	D	5,488,120	Jan 30, 1996	Knutson et al			
	E	6,025,346	Feb 15, 2000	Knutson et al			
	F	6,087,350	Jul 11, 2000	Johnson et al			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	G	WO 99/49870	Oct 7, 1999	PCT			
	H	WO 01/64251	Sep 7, 2001	PCT			
	I	WO 99/16451	Apr 8, 1999	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Rev. 2-92)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

017620/9324

SERIAL NO.:

09/891,814

APPLICANT:

Bishop et al

FILING DATE:

June 26, 2001

GROUP:

1614

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT:

(Use several sheets if necessary)

COPY OF PAPERS
ORIGINALLY FILED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,698,328	Oct 6, 1987	Neer, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	WO 92/05130	Apr 2, 1992	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY OF PAPERS
ORIGINALLY FILED

Sheet 1 of 4

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 2833.26

SERIAL NO.: 08/781,910

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT: Charles W. Bishop et al.

(Use several sheets if necessary)

FILING DATE: December 30, 1996

GROUP: 1205

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	2,383,446	06/04/41	Calcott et al.			
	AB	3,697,559	10/10/72	DeLuca et al.			
	AC	3,741,996	06/26/73	DeLuca et al.			
	AD	3,907,843	09/23/75	DeLuca et al.			
	AE	4,195,027	08/25/80	DeLuca et al.			
	AF	4,202,829	05/13/80	DeLuca et al.			
	AG	4,225,596	09/30/80	DeLuca et al.			
	AH	4,234,495	11/18/80	DeLuca et al.			
	AI	4,260,549	04/07/81	DeLuca et al.			
	AJ	4,362,710	12/07/82	Watanabe			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AU	BE-A-877 356	10/15/79	Belgium			
	AV	WO 90/10820	09/20/90	PCT			
	AW	WO 87/00834	02/12/87	PCT			
	AX	EP-A-0 390 097	10/03/90	EP			
	AY	0197514	10/15/86	EP			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BC	L.E. Reeve et al., "Biological Activity of 1 α -hydroxy Vitamin D ₃ in the Rat" <i>Arch. Biochem. Biophys.</i> 186, 1, Feb. 1978, pp. 164-167
BD	Sjoden et al., "Effects of 1 OHD ₂ on Bone Tissue" <i>Acta Endocrinol.</i> (Copenh.) 16, 4, Aug. 1984, pp. 564-568
BE	N. Brautbar, "Osteoporosis: Is 1,25-(OH) ₂ D ₃ of Value in Treatment?" <i>Nephron</i> 44, 1986, pp. 161-166
BF	<i>Physician's Desk Reference</i> , Edition 43, pp. 1746-1748

EXAMINER:

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY OF PAPERS
ORIGINALLY FILED

Sheet 2 of 4

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 2833.26

SERIAL NO.: 08/781,910

APPLICANT: Charles W. Bishop et al.

FILING DATE: December 30, 1996

GROUP: 1205

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AK	4,508,651	04/ /85	Baggiolini et al.			
	AL	4,554,106	11/19/85	DeLuca et al.			
	AM	4,555,364	11/19/85	DeLuca et al.			
	AN	4,588,716	05/13/86	DeLuca et al.			
	AO	4,661,294	04/28/87	Holick et al.			
	AP	4,689,180	08/25/87	DeLuca et al.			
	AQ	4,866,048	09/12/89	Calverley et al.			
	AR	5,063,221	11/05/91	Nishii et al.			
	AS	5,104,864	04/14/82	DeLuca et al.			
	AT	5,157,135	10/20/92	Tsuji et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AZ	8404527	11/22/84	WO			
	8A	0 562 497 A1	09/29/93	EP			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	8G	Y. Tanaka et al., <i>Endocrinology</i> , 1973, 92, pp. 417-422
	BH	O.H. Sorenson et al., <i>Clin. Endocrinol.</i> , 1977, 7, pp. 169S-175S
	BI	V. Hoikka et al., <i>Acta. Med. Scand.</i> , 1980, 207, pp. 221-224
	8J	Brown et al., <i>Lancet</i> , 1984, 1, pp. 1091-1093
	BK	J. Podenphant et al., <i>Acta Med Scand.</i> , 1985, 218, pp. 329-333

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY PAPERS
ORIGINALLY FILED

Sheet 3 of 4

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 2833.26

SERIAL NO.: 08/781,910

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT: Charles W. Bishop et al.

(Use several sheets if necessary)

FILING DATE: December 30, 1996

GROUP: 1205

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BL	Caniggia et al., <i>Calif Tissue Int.</i> , 1986, 38, pp. 328-332
BM	Duda et al., <i>J. Clin. Invest.</i> , 1987, 79, pp. 1249-1253
BN	Sommerfeldt et al., <i>J. Nutr.</i> , 1983, 11, pp. 2595-2600
BO	Zerwebh et al., <i>J. Clin. Endocrinol. Metabol.</i> , 1985, 60, pp. 615-617
BP	Horst et al., <i>Anal. Biochem.</i> , 1981, 116, pp. 189-203
BQ	Horst et al., <i>Biochem. J.</i> , 1982, 204, pp. 185-189
BR	Foldes et al., <i>Osteoporosis</i> 1987, C. Christianson et al. (eds.) Osteopress Aps, Copenhagen, pp. 971-973
BS	Guidelines for the Clinical Evaluation of Drugs Used in the Treatment of Osteoporosis, HEW (FDA) 80-3094, pp. 5-6 (1979)
BT	J.A. Kanis et al., Guidelines for Clinical Trials in Osteoporosis, A Position Paper of the European Foundation for Osteoporosis, <i>Osteoporosis Int.</i> , 1991, 1, pp. 182-188
BU	C. Christiansen et al., "Prevention of Early Postmenopausal Bone Loss: Controlled 2-Year Study in 315 Normal Females," <i>Europ J Clin Invest</i> , 1980, 10, pp. 273-279
BV	J.M. Pouilles et al., "Prevention of Post-Menopausal Bone Loss with 1 α -Hydroxy Vitamin D ₃ , A Three-Year Prospective Study," <i>Clin Rheumatol.</i> , 11, 1992, 4, pp. 492-497
BW	M.F. Holick et al., <i>Proc. Natl. Acad. Sci. USA</i> 68, 803-804 (1971)
BX	G. Jones et al., <i>Biochemistry</i> 14, 1250-1256 (1975)
BY	M.F. Holick et al., <i>Science</i> 180, 190, 191 (1973)
BZ	H.Y. Lam et al., <i>Science</i> 186, 1038-1040 (1974)
CA	S.M. Ott, C. H. Chesnut, <i>Annals of Int. Med.</i> 1989, 110:267-274
CB	J.C. Gallagher et al., <i>Annals of Int. Med.</i> 1990, 113:649-655
CC	J. Aloia et al., <i>Amer. J. Med.</i> 84:401-08 (1988)
CD	M. Shiraki et al., <i>Endocrinol. Japan</i> 32, 305-315 (1985)
CE	G.F. Jensen et al., <i>Clin. Endocrinol.</i> 16, 515-524 (1982)
CF	C. Christiansen et al., <i>Eur. J. Clin. Invest.</i> 11, 305-309 (1981)
CG	O.H. Sorensen et al., <i>Clin. Endocrinol.</i> 7, 169S-175S (1977)
CH	H. Ojimo et al., <i>Bone and Mineral</i> 3, 47-52 (1987)
CI	G. Sjoden et al., <i>J. Nutr.</i> 114, 2043-2046 (1984)
CJ	G. Sjoden et al., <i>Proc. Soc. Exp. Biol. Med.</i> 178, 432-436 (1985)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY OF PAPERS
ORIGINALLY FILED

Sheet 4 of 4

FORM 2-92 1-148-1 S. DEPARTMENT OF COMMERCE
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.: 2833.26
SERIAL NO.: 08/781,910
APPLICANT: Charles W. Bishop et al.
FILING DATE: December 30, 1996
GROUP: 1205

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CL	J.C. Gallagher et al., <i>J. Bone Min. Res.</i> ; 1994; 9:607-614
CM	E. Braunwald et al., <i>Harrison's Principles of Internal Medicine</i> : Part Eleven, "Disorders of Bone and Mineral Metabolism," Chapter 335, McGraw-Hill, New York, 1987, pp. 1860-1865
CN	W. Grab, <i>Z. Physiol. Chem.</i> , 243:63-89 (1936)
CO	F.G. McDonald, <i>J. Biol. Chem.</i> , 114:IVX (1936)
CP	A. Windaus et al., <i>Z. Physiol. Chem.</i> , 247:185-188 (1937)
CQ	DeLuca et al., <i>Arch. Biochem. Biophys.</i> , 124:122-128 (1968)
CR	<i>Merck Index</i> , S. Budavari (ed.), 11th ed., Merck & Co., Rahway, N.J. (1989) pp. 1579, #9930
CS	Barton et al., <i>JCS Perkin I</i> , 1976, 821-826
CT	Paaren et al., <i>J. Org. Chem.</i> , 1980, 45:3253
CU	S. Wientroub et al., "The Dichotomy in the Effects of 1,25 dihydroxy vitamin D ₃ and 24,25 dihydroxy vitamin D ₃ on Bone Gamma-Carboxyglutamic Acid-Containing Protein in Serum and Bone in vitamin D-Deficient Rats," <i>Calcif. Tissue Int.</i> (1987) 40:166-172
CV	Strugnell et al., <i>Biochem. Pharm.</i> Vol. 40:333-341 (1990)
CW	Martin and DeLuca, <i>Am. J. Physiol.</i> 216:1352-1359
CX	P.J. Kocienski et al., <i>J.C.S. Perkins I</i> , 1290-1293 (1979)
CY	M.Tsuji et al., <i>Bull. Chem. Soc. Jpn.</i> , Vol. 63, No. 8, 2233-2238 (1990)
CZ	D.R. Crump et al., <i>J.C.S. Perkins Trans. I</i> , 2731-2733 (1973)
DA	CHEMICAL ABSTRACTS, vol. 113, no. 1, 2 July 1990, Columbus, Ohio, US; abstract no. 6683y, Y. TACHIBANA, 'Preparation of 1beta-hydroxyvitamin D ₂ and D ₃ ,' page 6688; column 2; *abstract* & JP-A-02 011 563 (Nisshin Flour Milling Co.)
DB	CHEMISTRY LETTERS, no. 8, August 1985, Tokyo, JP, pages 1131-1132, H. Nemeto et al., 'A stereoselective synthesis of 1 alpha-hydroxy-vitamin D ₃ '; *the whole document*
DC	F. Sato et al., <i>Biochim. Biophys. Acta</i> , Vol. 1091 (1991) pp. 188-192

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620/9335
SERIAL NO.: 09/995,911
APPLICANT: Richard B. Mazess.
FILING DATE: November 28, 2001
GROUP: 1617



INFORMATION DISCLOSURE
STATEMENT BY APPLICANT:
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED

AUG 15 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>Beer</i>	Beer, et al., "A Phase I Trial of Pulse Calcitriol in Patients with Refractory Malignancies," <i>Cancer</i> , vol. 91, no. 12 (June 15, 2001) 2431-2439.
<i>Beer</i>	Beer, et al., "Weekly High-Dose Calcitriol and Docetaxel in Advanced Prostate Cancer," <i>Seminars in Oncology</i> , vol. 28, no. 4., Suppl 15 (August 2001) 49-55.

Q:\CLIENT\017620\9335\B0157425.1
07/23/02

EXAMINER

DATE CONSIDERED

7/7/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620/9324

SERIAL NO.: 09/891,814

APPLICANT: Bishop *et al.*

FILING DATE: June 26, 2001

GROUP: 1614

COPY OF PAPERS
ORIGINALLY FILED



INFORMATION DISCLOSURE
STATEMENT BY APPLICANT:

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>PK</i>	AA	4,391,802	Jul 5, 1983	Suda et al			
	AB	5,763,428	Jun 9, 1998	Knutson et al			
	AC	5,763,429	Jun 9, 1998	Bishop et al			
	AD	5,786,348	Jul 28, 1998	Bishop et al			
	AE	5,789,397	Aug 4, 1998	Bishop et al			
	AF	5,798,345	Aug 25, 1998	Knutson et al			
	AG	5,801,164	Sep 1, 1998	Knutson et al			
	AH	6,025,346	Feb 15, 2000	Knutson et al			
	AI	6,166,000	Dec 26, 2000	Bishop et al			
	AJ	6,211,168	Apr 3, 2001	Bishop et al			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
<i>PK</i>	AK	WO 94/05630	Mar 17, 1994	PCT			
	AL	WO 96/40153	Dec 19, 1996	PCT			
	AM	WO 96/40154	Dec 19, 1996	PCT			
	AN	WO 97/23242	Jul 3, 1997	PCT			
	AO	WO 98/56387	Dec 17, 1998	PCT			
	AP	WO 98/56389	Dec 17, 1998	PCT			
	AQ	WO 99/49027	Sep 30, 1999	PCT			
	AR	WO 00/03700	Jan 27, 2000	PCT			
	AS	WO 01/22974	Apr 5, 2001	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

7/7/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY OF PAPERS
ORIGINALLY FILED

Sheet 1 of 4

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 17620/9089

SERIAL NO.: 09/596,149

APPLICANT: Charles W. Bishop et al.

FILING DATE: February 23, 1998

GROUP:

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT:

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
K	2,383,446	06/04/41	Calcott et al.	7	Z	
	3,697,559	10/10/72	DeLuca et al.			
	3,741,996	06/26/73	DeLuca et al.			
	3,907,843	09/23/75	DeLuca et al.			
	4,195,027	03/25/80	DeLuca et al.			
	4,202,829	05/13/80	DeLuca et al.			
	4,225,596	09/30/80	DeLuca et al.			
	4,234,495	11/18/80	DeLuca et al.			
	4,260,549	04/07/81	DeLuca et al.			
	4,362,710	12/07/82	Watanabe			
	4,391,802	07/05/83	Suda et al.			
✓	4,508,651	04/85	Baggiolini et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
K	BE-A-877 356	10/15/79	Belgium	7	Z	
	WO 90/10620	09/20/90	PCT			
	WO 87/00834	02/12/87	PCT			
	EP-A-0 390 097	10/03/90	EP			
	0197514	10/15/86	EP			
	8404527	11/22/84	WO			
	0 562 497 A1	09/29/93	EP			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

K	L.E. Reeve et al., "Biological Activity of 1 α -hydroxy Vitamin D ₂ in the Rat" <i>Arch. Biochem. Biophys.</i> 186, 1, Feb. 1978, pp. 164-167
	Sjoden et al., "Effects of 1 OHD ₂ on Bone Tissue" <i>Acta. Endocrinol.</i> (Copenh.) 16, 4, Aug. 1984, pp. 564-568
	N. Brautbar, "Osteoporosis: Is 1,25-(OH) ₂ D ₃ of Value in Treatment?" <i>Nephron</i> 44, 1986, pp. 161-166
	<i>Physician's Desk Reference</i> , Edition 43, pp. 1746-1748 (2001)

EXAMINER

DATE CONSIDERED

7/7/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 17620/9089

SERIAL NO.: 09/596,149

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT:

APPLICANT: Charles W. Bishop et al.

(Use several sheets if necessary)

FILING DATE: February 23, 1998

GROUP:



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
K	4,554,106	11/19/85	DeLuca et al.			
	4,555,364	11/19/85	DeLuca et al.			
	4,588,716	05/13/86	DeLuca et al.			
	4,661,294	04/28/87	Holick et al.			
	4,689,180	08/25/87	DeLuca et al.			
	4,833,125 *	05/23/89	Neer et al.			
	4,866,048	09/12/89	Calverley et al.			
	5,063,221	11/05/91	Nishii et al.			
	5,104,864	04/14/82	DeLuca et al.			
	5,157,135	10/20/92	Tsuji et al.			
	5,372,996	12/13/94	Labrie			
	5,403,831	04/04/95	DeLuca et al.			
	5,448,120	09/05/95	Schaule et al.			
	5,602,116 *	02/11/97	Knutson et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
K	EP 0 503 630 A1 *	03/12/92	EP			
	WO 92/12165 *	07/23/92	PCT			
	WO 92/21355 *	12/10/92	PCT			
	WO 93/14763 *	08/03/93	PCT			
	WO 94/16711 *	08/04/94	PCT			
	EP 0 664 287 A1 *	07/26/95	EP			
	WO 96/40153 *	12/19/96	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

K	Y. Tanaka et al., <i>Endocrinology</i> , 1973, 92, pp. 417-422
	O.H. Sorenson et al., <i>Clin. Endocrinol.</i> , 1977, 7, pp. 169S-175S
	V. Hoikka et al., <i>Acta. Med. Scand.</i> , 1980, 207, pp. 221-224
	Brown et al., <i>Lancet</i> , 1984, 1, pp. 1091-1093
	J. Podenphant et al., <i>Acta Med Scand.</i> , 1985, 218, pp. 329-333

EXAMINER

DATE CONSIDERED

EXAMINER. Initial if citation considered, whether or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not considered. Include copy of this form with next
communication to applicant.

7/7/03



COPY OF PAPERS
ORIGINALLY FILED

Sheet 3 of 4

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT:

(Use several sheets if necessary)

ATTY. DOCKET NO.: 17620/9089
SERIAL NO.: 09/596,149
APPLICANT: Charles W. Bishop et al.
FILING DATE: February 23, 1998
GROUP:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


✓	Caniggia et al., <i>Calif Tissue Int.</i> , 1986, 38, pp. 328-332
	Duda et al., <i>J. Clinic Invest.</i> , 1987, 79, pp. 1249-1253
	Sommerfeldt et al., <i>J. Nutr.</i> , 1983, 11, pp. 2595-2600
	Zerwebh et al., <i>J. Clin. Endocrinol. Metabol.</i> , 1985, 60, pp. 615-617
	Horst et al., <i>Anal. Biochem.</i> , 1981, 116, pp. 189-203
	Horst et al., <i>Biochem. J.</i> , 1982, 204, pp. 185-189
	Foldes et al., <i>Osteoporosis</i> , 1987, C. Christianson et al. (eds.) Osteopress Aps, Copenhagen, pp. 971-973
	Guidelines for the Clinical Evaluation of Drugs Used in the Treatment of Osteoporosis, HEW (FDA) 80-3094, pp. 5-6 (1979)
	J.A. Kanis et al., Guidelines for Clinical Trials in Osteoporosis, A Position Paper of the European Foundation for Osteoporosis, <i>Osteoporosis Int.</i> , 1991, 1, pp. 182-188
	C. Christiansen et al., "Prevention of Early Postmenopausal Bone Loss: Controlled 2-Year Study in 315 Normal Females," <i>Europ J Clin Invest</i> , 1980, 10, pp. 273-279
	J.M. Pouilles et al., "Prevention of Early Postmenopausal Bone Loss with 1 α -Hydroxy Vitamin D ₃ , A Three-Year Prospective Study," <i>Clin Rheumatol.</i> , 11, 1992, 4, pp. 492-497
	M.F. Holick et al., <i>Proc. Natl. Acad. Sci. USA</i> 68, 803-804 (1971)
	G. Jones et al., <i>Biochemistry</i> 14, 1250-1256 (1975)
	M.F. Holick et al., <i>Science</i> 180, 190, 191 (1973)
	H.Y. Lam et al., <i>Science</i> 486, 1038-1040 (1974)
	S.M. Ott, C.H. Chesnut, <i>Annals of Int. Med.</i> 1989, 110:267-274
	J.C. Gallagher et al., <i>Annals of Int. Med.</i> 1990, 113:649-655
	J. Aloia et al., <i>Amer. J. Med.</i> 84:401-08 (1988)
	M. Shiraki et al., <i>Endocrinol. Japan</i> 32, 305-315 (1985)
	G.F. Jensen et al., <i>Clin. Endocrinol.</i> 16, 515-524 (1982)
	C. Christiansen et al., <i>Eur. J. Clin. Invest.</i> 11, 305-309 (1981)
	O.H. Sorensen et al., <i>Clin. Endocrinol.</i> 7, 169S-175S (1977)
	H. Orimo et al., <i>Bone and Mineral</i> 3, 47-52 (1987)
	G. Sjoden et al., <i>J. Nutr.</i> 114, 2043-2046 (1984)
	G. Sjoden et al., <i>Proc. Soc. Exp. Biol. Med.</i> 178, 432-436 (1985)
	J.C. Gallagher et al., <i>J. Bone Min. Res.</i> , 1994, 9:607-614
	E. Braunwald et al., <i>Harrison's Principles of Internal Medicine: Part Eleven, "Disorders of Bone and Mineral Metabolism,"</i> Chapter 335, McGraw-Hill, New York, 1987, pp. 1860-1865
	W. Grab, <i>Z. Physiol. Chem.</i> , 243:63-89 (1936)
	F.G. McDonald, <i>J. Biol. Chem.</i> , 114:IVX (1936)

EXAMINER

DATE CONSIDERED

7/7/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY PAPER
ORIGINALLY FILED

Sheet 4 of 4

FORM PT-3
(Rev. 2-92)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT:

(Use several sheets if necessary)

ATTY. DOCKET NO.: 17620/9089

SERIAL NO.: 09/596,149

APPLICANT: Charles W. Bishop et al.

FILING DATE: February 23, 1998

GROUP:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<input checked="" type="checkbox"/>	A. Windaus et al., <i>Z. Physiol. Chem.</i> , 247:185-188 (1937)
<input checked="" type="checkbox"/>	DeLuca et al., <i>Arch. Biochem. Biophys.</i> , 124:122-128 (1968)
<input checked="" type="checkbox"/>	<i>Merck Index</i> , S. Budavari (ed.), 11th ed., Merck & Co., Rahway, N.J. (1989) pp. 1579, #9930
<input checked="" type="checkbox"/>	Barton et al., <i>JCS Perkin I</i> , 1976, 821-826
<input checked="" type="checkbox"/>	Paaren et al., <i>J. Org. Chem.</i> , 1980, 45:3253
<input checked="" type="checkbox"/>	S. Wientroub et al. "The Dichotomy in the Effects of 1,25 dihydroxy vitamin D ₃ and 24, 25 dihydroxy vitamin D ₃ on Bone Gamma-Carboxyglutamic Acid-Containing Protein in Serum and Bone in vitamin D-Deficient Rats," <i>Calcif. Tissue Int.</i> (1987) 40:166-172
<input checked="" type="checkbox"/>	Strugnelli et al., <i>Biochem. Pharm.</i> Vol. 40:333-341 (1990)
<input checked="" type="checkbox"/>	Martin and DeLuca, <i>Am. J. Physiol.</i> 216:1352-1359 <i>1) BTE NEEDED</i>
<input checked="" type="checkbox"/>	P.J. Kocienski et al., <i>J.C.S. Perkins I</i> , 1290-1293 (1979)
<input checked="" type="checkbox"/>	M. Tsuji et al., <i>Bull. Chem. Soc. Jpn.</i> , Vol. 63, No. 8, 2233-2238 (1990)
<input checked="" type="checkbox"/>	D.R. Crump et al., <i>J.C.S. Perkins Trans. I</i> , 2731-2733 (1973)
<input checked="" type="checkbox"/>	CHEMICAL ABSTRACTS, vol. 113, no. 1, 2 July 1990, Columbus, Ohio, US; abstract no. 6683y, Y. TACHIBANA, 'Preparation of 1beta-hydroxyvitamin D ₂ and D ₃ , ' page 6688; column 2; abstract & JP-A-02 011 563 (Nisshin Flour Milling Co.)
<input checked="" type="checkbox"/>	CHEMISTRY LETTERS, no. 8, August 1985, Tokyo, JP, pages 1131-1132, H. Nemeto et al., 'A stereoselective synthesis of 1 alpha-hydroxy-vitamin D ₃ '
<input checked="" type="checkbox"/>	F. Sato et al., <i>Biochim. Biophys. Acta</i> , Vol. 1091 (1991) pp. 188-192
<input checked="" type="checkbox"/>	* Holick, M. F., "Noncalcemic Actions of 1,25-Dihydroxyvitamin D ₃ and Clinical Applications", <i>Bone</i> , Vol. 17, 2:107S-110S (1995)
<input checked="" type="checkbox"/>	* Knutson, et al., "Metabolism of 1α-Hydroxyvitamin D ₂ to activated Dihydroxyvitamin D ₂ Metabolites Decreases Endogenous 1α,25-Dihydroxyvitamin D ₃ in Rats and Monkeys", <i>Endocrinology</i> , Vol. 136, 11:4749-4753 (1995)
<input checked="" type="checkbox"/>	* Majewski, et al., "Inhibition of Tumor Cell-Induced Angiogenesis by Retinoids, 1,25-Dihydroxyvitamin D ₃ and their Combination", <i>Cancer Letters</i> , Vol. 75, 35-39 (1993)
<input checked="" type="checkbox"/>	Miller et al., "The Human Prostatic Carcinoma Cell Line LNCaP Expresses Biologically Active, Specific Receptors for 1α,25-Dihydroxyvitamin D ₃ ", <i>52 Cancer Res.</i> (1992):515-520
<input checked="" type="checkbox"/>	Strugnelli et al., "1α,24(S)-Dihydroxyvitamin D ₂ : a biologically active product of 1α-hydroxyvitamin D ₂ made in the human hepatoma, Hep3B," <i>310 Biochem. J.</i> (1995) pp. 233-241
<input checked="" type="checkbox"/>	Skowronski et al., "Actions Of Vitamin D ₃ Analogs on Human Prostrate Cancer Cell Lines: Comparison with 1,25-Dihydroxyvitamin D ₃ ," <i>136 Endocrinology</i> (1995) 20-26
<input checked="" type="checkbox"/>	Skowronski et al., "Vitamin D and Prostate Cancer: 1,25 Dihydroxyvitamin D ₃ Receptors and Actions in Human Prostate Cancer Cell Lines," <i>132 Endocrinology</i> (1993) 1952-1960

EXAMINER

DATE CONSIDERED

EXAMINER: *[Signature]* Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY OF PAPERS
ORIGINALLY FILED

Sheet 1 of 1

FORM PTO-1576 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.: 2833.26
SERIAL NO.: 08/781,910
APPLICANT: Charles W. Bishop et al.
FILING DATE: December 30, 1996
GROUP: 1205

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DB	4,391,802	07/05/83	Soda et al.			
DE	5,372,996	12/13/94	Labrie			
DF	5,403,831	04/04/95	DeLuca et al.			
DG	5,448,129	09/05/95	Schaule et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

M	DH	Miller et al., "The Human Prostatic Carcinoma Cell Line LNCaP Expresses Biologically Active, Specific Receptors for $1\alpha,25$ -Dihydroxyvitamin D_3 ," 52 <i>Cancer Res.</i> (1992) 515-520
	DI	Strugnell et al., " $1\alpha,24(S)$ -Dihydroxyvitamin D_2 : a biologically active product of 1α -hydroxyvitamin D_2 made in the human hepatoma, Hep3B," 310 <i>Biochem. J.</i> (1995) pp. 233-241
	DJ	Skowronski et al., "Actions Of Vitamin D_3 Analogs on Human Prostate Cancer Cell Lines: Comparison with $1,25$ -Dihydroxyvitamin D_3 ," 136 <i>Endocrinology</i> (1995) 20-26
	DK	Skowronski et al., "Vitamin D and Prostate Cancer: $1,25$ Dihydroxyvitamin D_3 Receptors and Actions in Human Prostate Cancer Cell Lines," 132 <i>Endocrinology</i> (1993) 1952-1960

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.